SGLT-2 inhibitors as cardioprotective agents in COVID-19

Coronavirus disease 2019 (COVID-19) caused by SARS-COV-2 virus is a global pandemic impacting nearly 10 million people worldwide. Since the initial detection in December 2019, this novel coronavirus has posed major challenges to the human race. The disease has a varied spectrum of presentation with respiratory system being most commonly affected followed by the cardiovascular (CV) system in later stages of the disease.1 Multiple risk factors accounting for an adverse outcome include older age, male sex and presence of comorbidities such as diabetes, hypertension, chronic kidney disease and obesity.
Source: Heart and Lung - Category: Intensive Care Authors: Source Type: research